28128-30-5

Usage

Uses

Used in Medicinal Chemistry:
1H-Purin-6-amine, 2-methoxyis used as a building block in medicinal chemistry for the synthesis of novel pharmaceutical compounds with purine-based structures. Its unique chemical properties and structural features make it a valuable component in the development of new drugs.
Used in Drug Development:
Due to its structural similarity to other purine derivatives, 1H-Purin-6-amine, 2-methoxymay possess biological activity, making it a potential candidate for the development of new therapeutic agents. Its potential applications in drug development include the creation of compounds with specific pharmacological properties, such as modulating cellular processes or targeting specific disease pathways.
Used in Research and Development:
1H-Purin-6-amine, 2-methoxyis also used in research and development for studying the properties and potential applications of purine-based compounds. Its unique structure and potential biological activity make it an interesting subject for scientific investigation, which may lead to the discovery of new therapeutic agents or a better understanding of purine-related biological processes.

InChI:InChI=1/C6H7N5O/c1-12-6-10-4(7)3-5(11-6)9-2-8-3/h2-3H,1H3,(H2,7,8,9,10,11)

Upstream product

• 124-41-4 sodium methylate 
• 1839-18-5 6-Amino-2-chlorpurin 
• 1839-18-5 2-chloroadenine 
• 5451-40-1 2,6-dichloro-7H-purine 
• 20419-68-5 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 77111-77-4 2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 77111-78-5 2-methoxy-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 24757-70-8 2'-deoxyspongosine 

Downstream Products

• 24723-77-1 2-Methoxyadenosine 
• 859211-32-8 9-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-2-methoxyadenine 

Relevant academic research and scientific papers

PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS

There are provided substituted purine and 3-deazapurine analogues, which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline metabolism, such as cancer, cell proliferative disorders, infectious diseases of different origin, immune-related disorders and neurodegenerative disorders. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Peptidyl α-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors

A series of peptidyl α-ketoamides with the general structure Cbz-l-Leu-d,l-AA-CONH-R were synthesized and evaluated as inhibitors for the cysteine proteases calpain I, calpain II, and cathepsin B. Nucleobases, methylpiperazine, and dimethylaminoalkyl groups were incorporated into the primed region of the inhibitors to generate compounds that potentially cross the blood-brain barrier. Two of these compounds (Cbz-Leu-d,l-Abu-CONH-(CH 2)3-adenin-9-yl and Cbz-Leu-d,l-Abu-CONH-(CH 2)3-(4-methylpiperazin-1-yl) have been shown to have useful concentrations in the brain in animals. The best inhibitor for calpain I was Cbz-Leu-d,l-Abu-CONH-(CH2)3-2-methoxyadenin-9-yl (Ki = 23 nM), and the best inhibitor for calpain II was Cbz-Leu-d,l-Phe-CONH-(CH2)3-adenin-9-yl (Ki = 68 nM). On the basis of the crystal structure obtained with heterocyclic peptidyl α-ketoamides, we have improved inhibitor potency by introducing a small hydrophobic group on the adenine ring. These inhibitors have good potential to be used in the treatment of neurodegenerative diseases.

SYNTHESIS OF SPONGOSINE

Reaction of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose with 2-methoxyadenine to form 9-(2’,3’,5’-tri-O-benzoyl-β-D-ribofuranosyl)-2-methoxyadenine, then deprotection of the 9-(2’,3’,5’-tri-O-benzoyl-β-D-ribofuranosyl)-2-methoxyadenine to form spongosine is described. Synthesis of intermediates for use in the synthesis of spongosine is also described.

Oligonucleotides containing consecutive 2'-deoxyisoguanosine residues: Synthesis, duplexes with parallel chain orientation, and aggregation

The 2'-deoxyisoguanosine phosphonates 3a and 4a and the phosphoramidites 3b and 4b were prepared as building blocks for solid-phase oligonucleotide synthesis. The diphenylcarbamoyl (dpc) residue was introduced as 2-oxo protecting group which stabilizes the N-glycosylic bond against hydrolysis and prevents the molecule from side reactions. The dpc-protected building blocks 4a,b were employed in solid-phase synthesis and were found to be much more efficient than the unprotected compounds 3a,b. Oligonucleotides with alternating (11) or consecutive isoguanine residues (13-15) were synthesized. They form duplexes with parallel chain orientation. The aggregate d(T4-iG4-T4) (15) containing four consecutive 2'-deoxyisoguanosine is shown to be a tetramer similar to that of d(T4-G4-T4).